US-based Omni Bio Pharmaceutical has named Bruce Schneider as the company's new chief executive officer (CEO), effective 1 January 2013. Omni Bio is involved in developing alternative uses of Alpha-1 antitrypsin (AAT), designed for ...
Tags: Pharmaceutical, New CEO, Omni Bio, AAT